




HEALTHCARE

Evolving Trends in Biopharmaceutical Licensing

Deal assessments, drivers and resisters

By Melissa Zebrowski

 [Table of Contents](#)

Melissa Zebrowski

Melissa Zebrowski has seven years of experience in healthcare and pharmaceutical policy research and analysis. During this time she has worked for five years as a consultant providing market research services in developed and emerging markets. Currently she is working as a pharmaceutical market analyst.

Copyright © 2008 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Evolving Trends in Biopharmaceutical Licensing

Executive Summary	10	
Introduction to biopharmaceutical licensing	10	
Biopharmaceutical deals and trends	11	
Drivers and resistors facing biopharmaceutical licensing	12	
Companies involved in biopharmaceutical licensing	13	
The evolutionary pattern of biopharmaceutical licensing	14	
Chapter 1	Introduction to biopharmaceuticals and licensing	16
Summary		16
Introduction		17
Overview of the biopharmaceutical industry		17
The Biopharma-Pharma relationship		18
The licensing process		21
Meeting the licensing challenge		22
Biopharma continues to shine		24
Chapter 2	Biopharmaceutical deals and trends	26
Summary		26
Introduction		27
Biopharmaceutical licensing trends		27
Number and average value of Biopharma licensing deals		28
Licensing deal partners		30
Biopharma's standing: out-licensing versus in-licensing deals		31
Licensing deal types		32
Licensing trends in drug development		34

The rising costs of early-stage licensing	35
Mid-stage deal-making: lucrative prospects	40
Therapeutic focus in Biopharma licensing	41

Chapter 3 Drivers and resisters of biopharmaceutical licensing 44

Summary	44
Introduction	45
Overview of drivers and resisters in biopharmaceutical licensing	45
Key drivers	46
Generating cash	46
Pharma turns to Biopharma to maintain revenue growth; Biopharma gaining an upper hand	48
Risk sharing	50
Access to expertise	50
Key resisters	52
Reduced control	52
Increasing complexity of licensing deals: positive for Biopharma but with a higher risk attached	52
Stricter regulatory and political environments	53
Future strategic direction	58

Chapter 4 Leading companies involved in biopharmaceutical licensing 62

Summary	62
Introduction	63
Who is looking to Biopharma and why?	63
Two sides of the Pharma coin: GlaxoSmithKline and Roche	64
GlaxoSmithKline: a Biopharma façade?	64
Roche: building upon an established presence in Biopharma	71
The Biopharma/Pharma dynamic	76
Amgen: the leading Biopharma	76
Gilead: diversification after market domination	80
Cephalon: a Biopharma out-licensor	83
Alnylam: a developer of novel therapeutics based on RNA interference	85

Chapter 5	The evolutionary pattern of biopharmaceutical licensing	90
	Summary	90
	Introduction	91
	The big deals of 2008: a sign of what is to come?	91
	Who holds the future to ImClone?	91
	The Roche and Genentech saga	92
	Biopharma to Biopharma: Genzyme and Isis	93
	Takeda looks to Biopharma for entry to the US market	94
	Pfizer and Wyeth	95
	Are M&As the new licensing?	97
	Potential arrival of biosimilars: a catalyst for Biopharma M&A	98
	The financial crisis and the future of Biopharma	99
	The promise of emerging markets	101
	Keys to future success	104
	Recommendations and strategies for future Biopharma licensing deals and alliances	105
Chapter 6	Appendix	110
	MedTRACK data	110
	Index	111

List of Figures

Figure 1.1:	Number of NMEs and BLAs approved by the US FDA	19
Figure 1.2:	Strengths of Biopharma and Pharma	21
Figure 1.3:	Overview of the pharmaceutical licensing process	23
Figure 1.4:	Global sales* of Biopharma vs. Pharma	24
Figure 2.5:	Number and average value of Biopharma licensing deals, 2001–08	28
Figure 2.6:	Number of top 20 Biopharma licensing deals by partner, 2001–08	30
Figure 2.7:	Number of Biopharma in- and out-licensing deals by partner, 2004–08	31
Figure 2.8:	Biopharma licensing by deal type, 2001–08	32
Figure 2.9:	Biopharma out-licensing distribution by clinical stage, 2001–08	34
Figure 2.10:	Early-stage deal models with associated pros & cons	36
Figure 2.11:	Early-stage alliances—number of deals and deal size, 2001–08	37
Figure 2.12:	Trends in technology, Biopharma out-licensing, 2002–07	38
Figure 2.13:	Number of Biopharma out-licensing deals (\$100m+ nominal deal value) by clinical stage, 2005–08	40
Figure 2.14:	Therapeutic focus in Biopharma licensing deals, 2005–08	41
Figure 3.15:	Drivers and resistors facing biopharmaceutical licensing	46
Figure 3.16:	Biopharma R&D spend	47
Figure 3.17:	Biopharma funding	47
Figure 3.18:	Progression of Biopharma’s involvement in licensing deals	49
Figure 3.19:	Estimated last patent expiry dates of selected proteins	56
Figure 3.20:	Future strategic directions for Biopharma in meeting current challenges	58
Figure 4.21:	Biopharma’s transition via forward and downward integration	64
Figure 5.22:	Announced number of Biopharma mergers & acquisitions, 2001–08	97
Figure 5.23:	Drug patent expiries in the US, 2008-2012	100
Figure 5.24:	Future licensing and alliance scenarios for Biopharma	104

List of Tables

Table 4.1:	GSK's licensing and alliance activity, 2008	67
Table 4.2:	GSK's licensing and alliance activity, 2007	68
Table 4.3:	GSK's licensing and alliance activity, 2006	69
Table 4.4:	GSK's licensing and alliance activity, 2005	70
Table 4.5:	Roche's licensing and alliance activity, 2008	71
Table 4.6:	Roche's licensing and alliance activity, 2007	72
Table 4.7:	Roche's licensing and alliance activity, 2006	73
Table 4.8:	Roche's licensing and alliance activity, 2005	74
Table 4.9:	Amgen's licensing and alliance activity, 2007-08	77
Table 4.10:	Amgen's licensing and alliance activity, 2005-06	78
Table 4.11:	Gilead's licensing and alliance activity, 2005-07	80
Table 4.12:	Cephalon's licensing and alliance activity, 2005-07	83
Table 4.13:	Alnylam's licensing and alliance activity, 2005-07	85
Table 5.14:	Sales in 7MM and pharmerging markets (\$m), 2003-07	101